secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sorrento Therapeutics, Inc. (—)
CIK:        0000850261
Form:       8-K
Filed at:   2023-02-13T23:59:59+00:00
Accession:  0001104659-23-018890
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sorrento Therapeutics files Chapter 11 bankruptcy after $156M arbitration award enforced
--------------------------------------------------------------------------------

- Filed voluntary Chapter 11 petitions on Feb 13, 2023 in Southern District of Texas.
- Triggered by court confirmation of $156.8M award to NantCell and $16.7M to NANTibody, with $50M enforcement stay.
- Company also received $125M award in separate Cynviloq arbitration against NantPharma.
- Debtors include wholly-owned subsidiary Scintilla Pharmaceuticals; operations continue under Bankruptcy Code.
- Bankruptcy intended to prevent asset levy and disruption to drug development pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/850261/000110465923018890/0001104659-23-018890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/850261/000110465923018890/tm236509d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-018890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer